Gut bacteria changes could be ‘warning sign for worsening Parkinson's symptoms'
Changes in specific bacteria in the mouth and gut of patients with Parkinson's disease could potentially be an early warning sign that symptoms of the condition are getting worse, a study suggests.
With the help of artificial intelligence (AI), scientists have linked these shifts to cognitive decline – problems with memory and learning – in people with the disease.
They suggest the toxins could one day be used as 'markers' for medics to pinpoint the Parkinson's patients at a higher risk of dementia, as well as being used to help develop targeted treatments for the disease.
Parkinson's disease is a progressive condition that affects the brain, with symptoms including involuntary shaking, known as tremors, as well as psychological problems such as depression, loss of balance, trouble sleeping and memory issues.
According to the Alzheimer's Society, around a third of people with Parkinson's eventually develop dementia.
Dr Saeed Shoaie, group leader of the quantitative systems biology (QTS) lab at King's College London, said: 'The human gut and oral bacterial communities are increasingly linked to neurodegenerative diseases.
'Disruptions in the gut-brain axis could trigger inflammation and immune responses that contribute to neuronal damage.
'A common gum disease bacterium like porphyromonas gingivalis has been discovered as a potential driver of Alzheimer's.'
For the study, led by experts at King's College London and published in the journal Gut Microbes, scientists analysed 228 spit and stool samples.
The samples came from 41 patients with Parkinson's and mild cognitive impairment, which causes problems with thinking and memory, 47 patients with Parkinson's and dementia and 26 healthy patients.
The team found that the gut of people with mild cognitive impairment contained more harmful bacteria, many of which are likely to have come from the mouth.
This bacteria releases toxins that can damage gut tissue, promote inflammation and potentially affect the brain, according to researchers.
For a more in-depth analysis, the team used AI to pinpoint the bacterial species and functions not usually picked up by traditional testing, allowing them to link toxins specifically to cognitive decline.
Dr Shoaie added: 'The emerging evidence underscores the potential importance of maintaining oral and gut health in mitigating or slowing neurodegenerative processes.
'As people with Parkinson's become increasingly reliant on carers, routine practices such as oral hygiene and nutritional intake may be neglected.
'Our findings suggest that promoting a healthy microbiome through consistent oral care, a balanced diet and potentially targeted probiotic interventions could support improved disease management in Parkinson's.'
Dr Frederick Clasen, research associate at the QTS lab, said: 'We don't yet know if the bacteria are causing the cognitive decline or if changes in the body due to Parkinson's allow these bacteria to grow.
'But our findings suggest they may play an active role in worsening symptoms.'
Dr Clasen suggests these markers could one day be used to develop targeted treatments.
'These toxins could be used as biological markers to identify patients at higher risk of dementia in Parkinson's,' he said.
'In the future, they might also be targets for new treatments that protect the brain by changing the gut environment.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
22 minutes ago
- Bloomberg
Astra's Early Test Fuels Hope for Cell Therapy Approach to Lupus
AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK drugmaker plows billions into the growing area of cell therapy called CAR-T. The medicine, which Astra gained in the takeover of Gracell Biopharmaceuticals Inc., has only just entered clinical trials. But the tiny study, conducted in Shanghai, had a stark impact on ten young volunteers whose disease wasn't controlled by earlier treatment. Six of them no longer showed signs of having lupus nine months after the one-time infusion, according to early results.
Yahoo
an hour ago
- Yahoo
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors Proceeds will support clinical development of lead program SB-007 in Stargardt disease Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areas BARCELONA, Spain, June 11, 2025 /PRNewswire/ -- SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners. The funding will be used to advance the clinical development of SpliceBio's lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study. SB-007 is the first dual adeno-associated viral (AAV) gene therapy cleared by the Food and Drug Administration (FDA) to enter clinical development for Stargardt disease. SB-007 has also received regulatory clearance for clinical development from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene that leads to progressive vision loss and blindness, with no approved treatments available. SB-007 is designed to address the underlying genetic cause of the disease by producing a functional copy of the full-length ABCA4 protein with the potential to treat all patients, regardless of their specific ABCA4 mutation. The proceeds will also be used to accelerate SpliceBio's pipeline of AAV gene therapy programs in ophthalmology, neurology, and other undisclosed indications that utilise the company's proprietary Protein Splicing platform. "This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology and beyond," said Miquel Vila-Perelló, Ph.D., Chief Executive Officer and Co-Founder of SpliceBio. "The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines." SpliceBio is redefining and expanding the scope of diseases that can be tackled with gene therapies by addressing a fundamental limitation of AAV vectors in their inability to deliver genes that exceed their limited packaging capacity of 4.7 kilobases. Many genetic disorders remain untreatable because the necessary gene is too large to fit into the AAV vectors. SpliceBio's unique Protein Splicing platform leverages the use of a family of proprietary, engineered proteins called inteins, originally developed at Princeton University. The company's technology enables the splitting of the gene into two (or more) transgenes that are then delivered using dual AAV vectors. Once inside the cell, the DNA of each transgene is transcribed into messenger RNA and translated into protein. SpliceBio's engineered inteins are designed to then assemble the full-length protein that is needed to treat the disease. Daniela Begolo, Managing Director at EQT Life Sciences, commented: "We are proud to support SpliceBio, a pioneer among the next-generation of genetic medicine companies. Its Protein Splicing platform is designed to offer a novel solution to deliver large genes with AAV, one of the field's most pressing challenges, and exemplifies our commitment to backing transformational science that can meaningfully benefit patients' lives." Laia Crespo, Partner at Sanofi Ventures, remarked: "With compelling data for its lead program, SB-007, and a highly differentiated platform, we are excited to support SpliceBio as it tackles a fundamental challenge for genetic medicines. By enabling the delivery of large and complex genes through its novel AAV vector Protein Splicing technology, SpliceBio has the potential to make a significant impact on the field of gene therapy and to deliver best-in-class therapies to patients." Carole Nuechterlein, Head of Roche Venture Fund, added: "We are impressed by the team's strong execution, the momentum behind SB-007 in Stargardt disease, and the platform's potential to unlock a new class of genetic medicines. We are proud to support SpliceBio at this pivotal stage of growth as they advance their lead program through clinical development and explore additional high-impact indications." In connection with the financing, Daniela Begolo, Managing Director at EQT Life Sciences, Laia Crespo, Partner at Sanofi Ventures, and Carole Nuechterlein, Head of Roche Venture Fund, will join the SpliceBio Board of Directors. About SpliceBioSpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company's lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio's pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio's platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit About SB-007SB-007 is an investigational Protein Splicing dual AAV gene therapy in development for the treatment of Stargardt disease. It is designed to restore expression of the native full-length ABCA4 protein in the retina. SB-007 has been granted Orphan Drug Designation from both the FDA in the US and the European Commission in Europe. In December 2024, SB-007 received FDA IND clearance, marking the first-ever clearance for a dual AAV gene therapy in Stargardt disease. Alongside initiation of the Phase 1/2 ASTRA study, with the announcement of the first patient dosed in March 2025, SpliceBio continues to advance POLARIS, a natural history study of the disease. Both studies are actively recruiting. For more information or to enquire about participation in the studies, please visit About EQT Life Sciences EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. More info: Follow EQT on LinkedIn, Twitter, YouTube and Instagram. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences aligning with Sanofi's mission to bring life-changing treatments to patients worldwide. For more information visit: About Roche Venture FundThe Roche Venture Fund is the corporate venture fund of Roche and invests in innovative life science companies. Over the past 20 years, the Roche Venture Fund has invested in over 60 companies globally and currently has a portfolio of around 30 companies located in 10 countries. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally and co-invests with leading venture funds, including other corporate venture funds, on a regular View original content: SOURCE SpliceBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Robots to perform surgery to cut NHS waiting times
Robotic surgery will be used en masse to cut NHS waiting times. On Wednesday, the head of the NHS will pledge a major expansion of robotic surgery to cover half a million procedures a year within a decade. Wes Streeting, the Health Secretary, said his life had been saved with the help of robots as he backed plans to use technology to boost productivity and cut waiting lists. The technique can be much more precise than the human hand, allowing greater dexterity as surgeons manipulate instruments using a 3D camera. Surgeons can get through operations more quickly, clearing waiting lists, and hospital stays will be halved because procedures are less invasive and cause less tissue damage. As a result, it can cut costs, help with a shortage of medics and get patients back to work more quickly. Robots will become the 'default' option for keyhole surgery, and be rolled out in many other cases, including hip operations and emergency procedures. Sir Jim Mackey, the NHS chief executive, will tell a conference of NHS leaders on Wednesday: 'The NHS has pledged to return to shorter elective waiting times by 2029, and we are using every tool at our disposal to ensure patients get the best possible treatment. 'Expanding the use of new and exciting tech such as robotic surgery will play a huge part in this. 'Not only does it speed up the number of procedures the NHS can do, but it also means better outcomes, a faster recovery and shorter hospital stays for patients.' The plans will mean around two-and-a-half to three million operations are delivered using robotic techniques in the next decade, bringing the total to half a million a year by 2035, up from 70,000 operations in 2023/24. Nine in 10 of all keyhole surgeries, such as the removal of organs affected by cancer, will be delivered with robot assistance within the next 10 years – up from one in five today. The NHS also expects to use the technology for increasing numbers of emergency operations. The rollout of the approach has halved hospital stays for some bladder cancer patients, bringing it down to just five days. Some experts believe that it can save more than £1,000 per patient. When robotic surgery was first introduced, the focus was largely on urological cancer surgery, but in recent years it has been introduced to several more areas, including bowel, gynaecology, ENT and orthopaedic procedures. It means operations like hysterectomies, which could involve a stay of up to a week, have reduced time in hospital to just 24 hours. The new forecasts, announced at NHS ConfedExpo in Manchester, follows national guidance on how robotic programmes should be delivered. Mr Streeting said: 'Innovative treatments and technologies that help fast track better outcomes for patients is how we transform our NHS and make it fit for the future. I know, myself, how important this is, when the NHS saved my life from kidney cancer with an operation led by a world-class surgeon being helped by a robot.' He said the moves would 'help cut waiting lists and get patients treated on time again'. Speaking ahead of the comprehensive spending review, which is expected to boost NHS funding by £30 billion a year by the next election, the Health Secretary said: 'We have put a record £26 billion into our NHS and social care, which includes cash to bring more cutting-edge tech into the health service to boost productivity, speed up recovery rates, and get people back to their best as soon as possible.' John McGrath, consultant surgeon at North Bristol NHS Trust, and chair of the NHS England Robotically-assisted Surgery steering committee, said: 'Robot-assisted surgery is a perfect example of innovation improving patients' care and transforming the way the NHS works – the number of procedures being carried is set to rapidly grow over the next 10 years according to our analysis. 'Robot-assisted surgery can also make complex operations less physically demanding for surgeons, with the potential to reduce strain on surgical teams, allowing a greater number of complex surgeries to be carried out each day.' Last year, patients at Liverpool University Hospitals NHS Foundation Trust became the first in Europe to be offered robotic-assisted surgery for head and neck cancers. Robotic assistance enables surgeons to access tumours through a single incision or natural orifice, such as through the mouth, with surgical instruments that can then work more easily in the tight space of the throat and airway. It means surgeons at Aintree University Hospital can remove tumours of the throat that previously would not have been accessible through the mouth. In some cases where tumours were unable to be removed through the mouth, without the use of robotic assistance, patients would have needed big operations to split their jaw to reach the cancer. This causes a lot of pain, a complicated hospital stay for up to two or three weeks with feeding tubes, and usually requires a tracheostomy tube for a period, to ensure patients can breathe safely. Matthew Taylor, chief executive of the NHS Confederation, said the expansion could bring 'significant efficiency gains' and improve outcomes for patients. However, he said: 'To achieve these productivity boosts requires the upfront investment in robotic surgery technologies, which can often be very expensive. This is why it is so important for the Government to continue to increase capital investment into the health service to make up for decades of underinvestment.' Kate Seymour, head of external affairs at Macmillan Cancer Support, said: 'We know that many people living with cancer across the country are facing long delays for care, and it's exciting developments, like those in robotic surgery announced today, that form an essential piece of the puzzle for sparking a much-needed revolution in cancer care.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
